| Trial ID: | L0727 |
| Source ID: | NCT04130321
|
| Associated Drug: |
Camu camu
|
| Title: |
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Overweight;Microtia;Endotoxemia;Metabolic Syndrome;Insulin Resistance;Non-Alcoholic Fatty Liver Disease
|
| Interventions: |
Dietary Supplement: Camu camu;Dietary Supplement: Placebo
|
| Outcome Measures: |
Change in Gut Microbiota Composition and Diversity;Change in fat accumulation in the liverChange in Endotoxemia;Change in Intestinal permeability;Change in Inflammation state of the tissue;Change in Short chain and branched chain fatty acids in the feces;Change in gut health;Change in stool consistency;Change in Glucose homeostasis;Change in Glucose homeostasis;Change in Glucose homeostasis;Change in Glucose homeostasis;Change in Lipid profile;Change in anthropometric measurements;Change in anthropometric measurements;Change in body composition;Change in chronic inflammation;Change in liver health;Change in gene expression levels;Change in circulating levels of plasma metabolites;Change in camu camu-derived metabolites present in stool;Change in blood pressure
|
| Sponsor/Collaborators: |
Laval University
|
| Gender: |
All
|
| Age: |
18 Years75 Years
|
| Phases: |
Not applicable
|
| Enrollment: |
35
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
| Start Date: |
03/10/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 September 2021
|
| Locations: |
Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT04130321
|
